We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.
The company’s guidance centers on “continued business development” in 2026 with near-term clinical, regulatory and BD catalysts over the next 6–12 months and a clear goal to license its crofelemer rare-disease program: target filing of an NDA for MVID in first half of 2027 (MVID global prevalence ≈200 patients) following completion of a fully enrolled placebo‑controlled trial (with ongoing treatment‑only extension), pursuit of FDA Breakthrough designation and EMA PRIME, and parallel Phase II randomized double‑blind placebo‑controlled development in short bowel syndrome‑IF (SBS‑IF; U.S. patient estimate ≈12,000) where third‑party market estimates put opportunity at ~$8 billion; proof‑of‑concept investigator data in three pediatric IF patients showed parenteral‑support reductions of 12%–37% (12.5%–15.6% in two SBS patients, ~37% in one MVID), with even 5% reductions described as meaningful; financial guidance emphasizes non‑dilutive funding (Future Pak licensing: $18M upfront with $16M received to date, $2M conditional, ~$20M in potential milestones and >$3M additional payments reported, Future Pak also paid $3M tied to termination of a buy‑back provision), Jaguar to remain manufacturer and recognize manufacturing revenue, Q4 2025 net revenue ≈$3.2M (+5% vs Q3 2025 $3.1M; −8% vs Q4 2024 $3.5M), 2025 total net revenue ≈$11.5M (≈$11.2M from Mytesi and Canalevia‑CA1), Mytesi prescription volume down ~3.7% in 2025 vs 2024 (Q4 2025 vs Q3 2025 down ~5.8%; Q4 2025 vs Q4 2024 down ~12.2%), loss from operations increased $15.1M to $45.9M in 2025, Non‑GAAP Recurring EBITDA net loss $48.1M (2025) vs $35.9M (2024), net loss attributable to common shareholders $53.6M (2025) vs $38.5M (2024), and the company expects these clinical, regulatory and BD milestones to drive partnership discussions and additional non‑dilutive funding.
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Combined net Q4 2025 revenue of approximately $3.2M, an increase of ~5% versus Q3 2025 (~$3.1M). Full-year 2025 net revenue totaled ~$11.5M, with ~$11.2M generated by Mytesi and Canalevia-CA1.
Investigator-initiated study (UAE) demonstrated reduction in parenteral support of 12%–37% (two pediatric SBS patients: 12.5%–15.6%; one MVID patient: up to 37%) with no safety issues reported. Patients treated >1 year and experienced relapse upon treatment cessation, supporting durable clinical benefit signals.
MVID placebo-controlled trial is fully enrolled with an amendment permitting treatment-only extension; target New Drug Application (NDA) for MVID in H1 2027. Company holds Orphan Designations in U.S. and EU for MVID and SBS-IF, and expects to pursue Breakthrough/PRIME designations. Company cites large addressable market for SBS (~$8B market estimate) and estimated ~12,000 U.S. SBS-IF patients (2021).
Clear corporate strategy to shift focus to late-stage crofelemer development for rare intestinal-failure indications, pursue licensing/partnerships to secure non-dilutive funding, and leverage manufacturing capability as a profit center following the Future Pak agreement.
Greetings, and welcome to Jaguar Health Investor Webcast. [Operator Instructions] Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the Company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on current available information and Management's current assumptions, expectations, and projections about future events. While Management believes its assumptions, expectations and projections are reasonable in the view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The Company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the Forward-Looking Statements and Risk Factors sections of the Company's Form 10-K for the year 2025, which was filed with the SEC on April 7, 2026, and its other filings with the SEC, which are available in the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looki...